Catalyzing Breakthroughs: Biospecimen Exchange for Neurological Disorders
BioSEND is a biorepository operated by Indiana University with funding from the National Institute of Neurological Disorders and Stroke (NINDS). Our primary function is to manage biospecimens for research studies of more than 25 different neurological diseases and disorders, including Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxias, traumatic brain injury, and many others.
Biospecimen management expertise
BioSEND banks samples for many neurodegenerative, neuropsychiatric, and other neurological conditions. We accept samples from new, ongoing, or completed studies, and can receive a wide range of biospecimens, including blood derivatives, spinal fluid, tissue, urine, and stool, with options to expand based on your needs.
Discover banking services at BioSENDCollaboration with Research Studies
BioSEND deploys clear protocols for study coordination. Our services for new studies include protocol-specific procedure manuals, remote site training, and streamlined kit supplies. Sample reconciliation ensures accuracy, while our online catalogs simplify sample identification.
Explore study coordination servicesWide Range of Biospecimens
Researchers worldwide can request to access BioSEND's diverse repository of samples, including those associated with Parkinson's disease (PD), Huntington's disease (HD), Spinocerebellar ataxia (SCA), Lewy Body Dementia (LBD), and other neurological and neuropsychiatric conditions. Our collection offers a wide array of sample types, such as CSF, DNA, PBMC, plasma, RNA, serum, urine, and more.
Access samples at BioSEND
Publication Impact: Advancing Research with BioSEND Samples
Witness the progress researchers achieve by accessing BioSEND's diverse sample repository. From Parkinson's disease (PD) to Huntington's disease (HD) and beyond, our collection propels neurological and neuropsychiatric studies forward.
Discover publicationsMiddleton JS, et al. (2023) Seed amplification assay results illustrate discrepancy in Parkinson's disease clinical diagnostic accuracy and error rates. J Neurol. 2023 Dec;270(12):5813-5818.